Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
l�ll
Actualites sur les modalites therapeutiques des uveites de Smet MDJ Fr Ophtalmol 2005[May]; 28 (5): 556-61The immunosuppression required for the treatment of uveitis can be achieved through conventional agents or through the use of specific modulators of inflammation. Whatever the choice, it is important to limit side effects: by restricting access to certain drugs in patients presenting a high risk of complications (tuberculosis screening before using Remicade), reducing side effects through preventive measures (use of alendronates during oral corticotherapy), or choosing a local delivery route (intraocular triamcinolone). Intraocular triamcinolone has certain beneficial characteristics such as high local dosage without systemic effect. However, it can cause a pressure rise in 10% to 20% of patients. It requires certain precautions when given to prevent development of a pseudo-endophthalmitis. Remicade is a novel synthetic immunosuppressant directed against TNF-alpha. This chimeric antibody can be useful in the treatment of severe uveitis that is unresponsive to conventional therapy. It is currently being tested in clinical trials in uveitis both in Europe and the USA.|Anti-Inflammatory Agents/therapeutic use[MESH]|Antibodies, Monoclonal/adverse effects/therapeutic use[MESH]|Humans[MESH]|Immunosuppression Therapy/methods[MESH]|Immunosuppressive Agents/adverse effects/therapeutic use[MESH]|Infliximab[MESH]|Uveitis/*drug therapy/immunology[MESH] |